<DOC>
	<DOCNO>NCT00679133</DOCNO>
	<brief_summary>In study , MGCD265 , new anticancer drug investigation , give daily 7 day / 7 day schedule patient advanced malignancy study safety profile .</brief_summary>
	<brief_title>Safety Study Oral MGCD265 Administered With Interruption Subjects With Advanced Malignancies</brief_title>
	<detailed_description>MGCD265 belong new class drug anticancer potential , know tyrosine kinase inhibitor . MGCD265 show slow growth human cancer cell mice . Clinical study pursue evaluate safety MGCD265 cancer patient . In study , oral MGCD265 administer daily 7 day / 7 day schedule patient advanced malignancy .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Patients advance metastatic unresectable malignancy refractory standard therapy and/or exist therapy likely achieve clinical benefit . The patient 's disease must histologically confirm ; Evaluable disease ; Last dose prior chemotherapy , radiation therapy , investigational agent occur least 4 week start therapy Cycle 1 Day 1 ; Recovery adverse effect prior therapy time enrollment ≤ grade 1 ( exclude alopecia ) ; Age ≥ 18 year ; Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 ; Life expectancy great 3 month follow study entry ; Adequate renal function ; Adequate hepatic parameter ; Adequate bone marrow function ; A negative serum pregnancy test screen woman childbearing potential ( WOCBP ) ; Agreement WOCBP men whose sexual partner WOCBP use two method adequate contraception hormonal barrier method ) prior study entry duration study . WOCBP men whose sexual partner WOCBP must continue use two method contraception 28 day 90 day , respectively , last dose study medication ; Ability understand willingness sign write informed consent document ; Willingness ability comply study visit activity perform study center ; For Expanded MTD Cohort , subject must tumor accessible biopsy . Subjects uncontrolled concurrent illness ; Subjects history cardiovascular illness ; Subjects QTc &gt; 470 msec ( include subject medication ) ; Subjects leave ventricular ejection fraction ( LVEF ) &lt; 50 % ; Subjects leukemias myelodysplastic syndrome ; Immunocompromised subject ; Subjects history autologous bone marrow transplant ( BMT ) within previous five year , subject organ transplant allogeneic BMT ; Subjects lung tumor lesion increase likelihood bleeding , include : history hemoptysis ; evidence cavitation ; invasion aorta pulmonary artery tumor ; Subjects history brain metastasis leptomeningeal disease ; subject tumor likely metastasize brain scan perform within 2 month start study rule brain metastasis ( example breast , lung , melanoma , sarcoma , etc . ) ; Subjects unable swallow oral medication preexist gastrointestinal disorder might interfere proper absorption oral drug ; Subjects history major surgery within 28 day first receipt study drug ; Nursing pregnant woman ; Subjects diseases , metabolic dysfunction , physical examination finding , clinical laboratory finding , opinion Investigator , contraindicate use MGCD265 Drug Product may render subject excessively high risk treatment complication ; Subjects know hypersensitivity component MGCD265 Drug Product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>c-Met</keyword>
	<keyword>VEGFR</keyword>
	<keyword>Ron</keyword>
	<keyword>Cancer</keyword>
	<keyword>Tumor</keyword>
	<keyword>Safety</keyword>
	<keyword>Phase 1</keyword>
</DOC>